Transmitted drug resistance in nonsubtype B HIV-1 infection

HIV Therapy

Volumn 3, Issue 5, 2009, Pages 447-465

  Chan, Philip A ^a   Kantor, Rami ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Diversity; Drug resistance; HIV 1; Nonsubtype B; Resistance transmission; Transmitted drug resistance; Treatment naive

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NONHUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSMITTED DRUG RESISTANCE; VIRUS MUTATION;

EID: 70349388189     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.30     Document Type: Review

References (219)

1. Clavel F, Hance AJ: HIV drug resistance. N. Engl. J. Med. 350, 1023-1035 (2004). (Pubitemid 38269279)
2. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362, 2002-2011 (2003).
3. Kozal MJ: Drug-resistant human immunodefiency virus. Clin. Microbiol. Infect. 15(Suppl. 1), 69-73 (2009).
4. Daar ES: Emerging resistance profiles of newly approved antiretroviral drugs. Top. HIV Med. 16, 110-116 (2008).
5. Shafer RW, Schapiro JM: HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67-84 (2008).
6. Wainberg MA: HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl. 3), S63-S68 (2004). ■ Focuses on the susceptibility of different HIV-1 subtypes to antiretroviral therapy and the development of drug resistance.
7. Kantor R, Katzenstein D: Drug resistance in nonsubtype B HIV-1. J. Clin. Virol. 29, 152-159 (2004).
8. Deroo S, Robert I, Fontaine E et al.: HIV-1 subtypes in Luxembourg, 1983-2000. AIDS 16, 2461-2467 (2002).
9. Hirsch MS, Gunthard HF, Schapiro JM et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47, 266-285 (2008). ■ Current guidelines for drug-resistance testing followed by most institutions in the developed world.
10. Little SJ, Holte S, Routy JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385-394 (2002). (Pubitemid 34851830)
11. Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279, 1977-1983 (1998).
12. Wensing AM, van de Vijver DA, Angarano G et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192, 958-966 (2005). ■ Large study comparing the prevalence of transmitted drug resistance (TDR) in subtype B and nonsubtype B HIV-1 in Europe.
13. Cane P, Chrystie I, Dunn D et al.: Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331, 1368 (2005).
14. Yerly S, von Wyl V, Ledergerber B et al.: Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21, 2223-2229 (2007). (Pubitemid 350287221)
15. Katabira ET, Oelrichs RB: Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 21(Suppl. 4), S5-S10 (2007).
16. Gilks CF, Crowley S, Ekpini R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505-510 (2006). (Pubitemid 44142772)
17. Galarraga O, ME O'Brien, Gutierrez JP et al.: Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS 21(Suppl. 4), S97-S103 (2007).
18. Boyd MA, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS 21(Suppl. 4), S55-S63 (2007).
19. Renaud-Thery F, Nguimfack BD, Vitoria M et al.: Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 21(Suppl. 4), S89-S95 (2007).
20. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008).
21. Vandamme AM, Sonnerborg A, Ait-Khaled M et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir. Ther. 9, 829-848 (2004). (Pubitemid 40040258)
22. Gazzard BG: British HIV Association Guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy 2008. HIV Med. 9, 563-608 (2008).
23. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl. 2), 1-13 (2008). ■ Excellent overview of the international approach to monitoring TDR in resource-poor settings as presented by the WHO.
24. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther. 13(Suppl. 2), 25-36 (2008). (Pubitemid 352019087)
25. Booth CL, Geretti AM: Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J. Antimicrob. Chemother. 59, 1047-1056 (2007).
26. Shet A, Berry L, Mohri H et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41, 439-446 (2006).
27. Smith D, Moini N, Pesano R et al.: Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin. Infect. Dis. 44, 456-458 (2007). (Pubitemid 46147633)
28. Ghosn J, Pellegrin I, Goujard C et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20, 159-170 (2006).
29. Bon I, Gibellini D, Borderi M et al.: Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J. Clin. Virol. 38, 313-320 (2007). (Pubitemid 46413996)
30. Metzner KJ, Rauch P, Walter H et al.: Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19, 1819-1825 (2005).
31. Paolucci S, Baldanti F, Campanini G et al.: Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J. Med. Virol. 65, 207-217 (2001). (Pubitemid 32816689)
32. Simen BB, Simons JF, Hullsiek KH et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199, 693-701 (2009).
33. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ: Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78, 4234-4247 (2004). (Pubitemid 38437228)
34. Peuchant O, Thiebaut R, Capdepont S et al.: Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22, 1417-1423 (2008).
35. Johnson JA, Li JF, Morris L et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192, 16-23 (2005). (Pubitemid 40863852)
36. Palmer S, Kearney M, Maldarelli F et al.: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype ana lysis. J. Clin. Microbiol. 43, 406-413 (2005). (Pubitemid 40096331)
37. Roquebert B, Malet I, Wirden M et al.: Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 20, 287-289 (2006).
38. Johnson JA, Li JF, Wei X et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5, e158 (2008).
39. Kantor R: Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr. Opin. Infect. Dis. 19, 594-606 (2006).
40. Kantor R, Katzenstein D: Polymorphism in HIV-1 nonsubtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5, 25-35 (2003). (Pubitemid 36873892)
41. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20, W13-W23 (2006).
42. Robertson DL, Anderson JP, Bradac JA et al.: HIV-1 nomenclature proposal. Science 288, 55-56 (2000).
43. McCutchan FE: Global epidemiology of HIV. J. Med. Virol. 78(Suppl. 1), S7-S12 (2006).
44. Johnson VA, Brun-Vezinet F, Clotet B et al.: Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16, 138-145 (2008).
45. Kantor R, Katzenstein DA, Efron B et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2, e112 (2005).
46. Ravela J, Betts BJ, F Brun-Vezinet et al.: HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J. Acquir. Immune Defic. Syndr. 33, 8-14 (2003). (Pubitemid 36547235)
47. Schmidt B, Walter H, Zeitler N, Korn K: Genotypic drug resistance interpretation systems - the cutting edge of antiretroviral therapy. AIDS Rev. 4, 148-156 (2002). (Pubitemid 35251992)
48. Snoeck J, Kantor R, Shafer RW et al.: Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50, 694-701 (2006). (Pubitemid 43190984)
49. Sturmer M, Doerr HW, Preiser W: Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion? Curr. Drug Targets Infect. Disord. 3, 373-382 (2003). (Pubitemid 38016624)
50. Bennett DE, Camacho RJ, Otelea D et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4, e4724 (2009). ■■ Current surveillance drug-resistance mutation list for the definition of TDR mutations.
51. Shafer RW, Rhee SY, Pillay D et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21, 215-223 (2007).
52. Clemente JC, Hemrajani R, Blum LE, Goodenow MM, Dunn BM: Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42, 15029-15035 (2003). (Pubitemid 38031700)
53. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J: pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J. Virol. 71, 6348-6358 (1997).
54. Pieniazek D, Rayfield M, Hu DJ et al.: Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 14, 1489-1495 (2000). (Pubitemid 30687672)
55. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT: The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J. Acquir. Immune Defic. Syndr. 49, 196-204 (2008). ■ TDR comparison according to different mutation lists in a large UK population.
56. Eshleman SH, Husnik M, Hudelson S et al.: Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 21, 1165-1174 (2007). (Pubitemid 46763287)
57. Viani RM, Peralta L, Aldrovandi G et al.: Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J. Infect. Dis. 194, 1505-1509 (2006). (Pubitemid 44851891)
58. Corvasce S, Violin M, Romano L et al.: Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir. Ther. 11, 329-334 (2006). (Pubitemid 43823551)
59. Oette M, Kaiser R, Daumer M et al.: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J. Acquir. Immune Defic. Syndr. 41, 573-581 (2006). (Pubitemid 43756138)
60. Chaix ML, Descamps D, Wirden M et al.: Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23, 717-724 (2009).
61. Alvarez M, Garcia F, Martinez NM et al.: Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. J. Med. Virol. 70, 10-13 (2003). (Pubitemid 36368858)
62. Balotta C, Facchi G, Violin M et al.: Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by ana lysis of reverse transcriptase and protease sequences. J. Acquir. Immune Defic. Syndr. 27, 499-505 (2001). (Pubitemid 32801080)
63. Brennan CA, Stramer SL, Holzmayer V et al.: Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion 49, 125-133 (2009).
64. Frange P, Galimand J, Vidal N et al.: New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study. Retrovirology 5, 69 (2008).
65. Hanna GJ, Balaguera HU, Freedberg KA et al.: Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J. Infect. Dis. 188, 986-991 (2003).
66. Parker MM, Gordon D, Reilly A et al.: Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naive, HIV-infected individuals in New York State. AIDS Patient Care STDS 21, 644-652 (2007).
67. Snoeck J, Van Laethem K, Hermans P et al.: Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J. Acquir. Immune Defic. Syndr. 35, 279-285 (2004).
68. Tramuto F, Vitale F, Bonura F, Romano N: Detection of HIV type 1 non-B subtypes in Sicily, Italy. AIDS Res. Hum. Retroviruses 20, 251-254 (2004). (Pubitemid 38280937)
69. Bessong PO, Larry Obi C, Cilliers T et al.: Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res. Hum. Retroviruses 21, 103-109 (2005). (Pubitemid 40179807)
70. Gordon M, De Oliveira T, Bishop K et al.: Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J. Virol. 77, 2587-2599 (2003). (Pubitemid 36222783)
71. Pillay C, Bredell H, McIntyre J, Gray G, Morris L: HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res. Hum. Retroviruses 18, 605-610 (2002). (Pubitemid 34579540)
72. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI: Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. AIDS 22, 2210-2212 (2008).
73. Koch N, Ndihokubwayo JB, Yahi N, Tourres C, Fantini J, Tamalet C: Genetic ana lysis of hiv type 1 strains in Bujumbura (Burundi): predominance of subtype c variant. AIDS Res. Hum. Retroviruses 17, 269-273 (2001). (Pubitemid 32113576)
74. Tovanabutra S, Beyrer C, Sakkhachornphop S et al.: The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res. Hum. Retroviruses 20, 465-475 (2004).
75. Watanaveeradej V, Benenson MW, Souza MD et al.: Molecular epidemiology of HIV type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV type 1 genotyping. AIDS Res. Hum. Retroviruses 22, 801-807 (2006). (Pubitemid 44735008)
76. Han X, Zhang M, Dai D et al.: Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference. AIDS Res. Hum. Retroviruses 23, 357-364 (2007). (Pubitemid 46608555)
77. Liao L, Xing H, Li X et al.: Genotypic ana lysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res. Hum. Retroviruses 23, 1062-1065 (2007). (Pubitemid 47492349)
78. Zhong P, Kang L, Pan Q et al.: Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China. J. Acquir. Immune Defic. Syndr. 34, 91-101 (2003). (Pubitemid 37100118)
79. Zhong P, Pan Q, Ning Z et al.: Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res. Hum. Retroviruses 23, 847-856 (2007). (Pubitemid 47267490)
80. Hsu LY, Subramaniam R, Bacheler L, Paton NI: Characterization of mutations in CRF01-AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore. J. Acquir. Immune Defic. Syndr. 38(1), 5-13 (2005).
81. Ly N, Recordon-Pinson P, Phoung V et al.: Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs. AIDS Res. Hum. Retroviruses 21, 971-976 (2005).
82. Ishizaki A, Cuong NH, Thuc PV et al.: Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Vietnam. AIDS Res. Hum. Retroviruses 25, 175-182 (2009).
83. Tee KK, Kamarulzaman A, Ng KP: Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res. Hum. Retroviruses 22, 121-124 (2006). (Pubitemid 43277146)
84. Ananworanich J, Phanuphak N, de Souza M et al.: Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J. Acquir. Immune Defic. Syndr. 49, 151-155 (2008).
85. Auswinporn S, Jenwitheesuk E, Panburana P, Sirinavin S, Vibhagool A, Chantratita W: Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women. Southeast Asian J. Trop. Med. Public Health 33, 818-821 (2002).
86. Chang SY, Chen MY, Lee CN et al.: Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J. Antimicrob. Chemother. 61, 689-693 (2008).
87. Arora SK, Gupta S, Toor JS, Singla A: Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res. Hum. Retroviruses 24, 125-130 (2008). (Pubitemid 351282103)
88. Deshpande A, Recordon-Pinson P, Deshmukh R et al.: Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res. Hum. Retroviruses 20, 1032-1035 (2004). (Pubitemid 39369712)
89. Eshleman SH, Hudelson SE, Gupta A et al.: Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res. Hum. Retroviruses 21, 93-97 (2005). (Pubitemid 40179805)
90. Kandathil AJ, Kannangai R, Abraham OC, Sudarsanam TD, Pulimood SA, Sridharan G: Genotypic resistance profile of HIV-1 protease gene: a preliminary report from Vellore, south India. Indian J. Med. Microbiol. 26, 151-154 (2008). (Pubitemid 351652297)
91. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS: Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res. Hum. Retroviruses 24, 987-990 (2008).
92. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS: Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Res. Hum. Retroviruses 23, 489-497 (2007). (Pubitemid 46700880)
93. Soheilli ZS, Ataiee Z, Tootian S et al.: Presence of HIV-1 CRF35-AD in Iran. AIDS Res. Hum. Retroviruses 25, 123-124 (2009).
94. Soundararajan L, Karunaianandham R, Jauvin V et al.: Characterization of HIV-1 isolates from antiretroviral drug-naive children in southern India. AIDS Res. Hum. Retroviruses 23, 1119-1126 (2007). (Pubitemid 47571931)
95. Balakrishnan P, Kumarasamy N, Kantor R et al.: HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res. Hum. Retroviruses 21, 301-305 (2005). (Pubitemid 40632362)
96. Pandrea I, Descamps D, Collin G et al.: HIV type 1 genetic diversity and genotypic drug susceptibility in the Republic of Moldova. AIDS Res. Hum. Retroviruses 17, 1297-1304 (2001). (Pubitemid 32911635)
97. Zarandia M, Tsertsvadze T, Carr JK, Nadai Y, Sanchez JL, Nelson AK: HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. AIDS Res. Hum. Retroviruses 22, 470-476 (2006). (Pubitemid 43787774)
98. Kolupajeva T, Aldins P, Guseva L et al.: HIV drug resistance tendencies in Latvia. Cent. Eur. J. Public Health 16, 138-140 (2008).
99. Vazquez de Parga E, Rakhmanova A, Perez-Alvarez L et al.: Analysis of drug resistance-associated mutations in treatment-naive individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J. Med. Virol. 77, 337-344 (2005). (Pubitemid 41395863)
100. Rodrigues R, Scherer LC, Oliveira CM et al.: Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res. 116, 201-207 (2006). (Pubitemid 43221733)
101. Sa-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, Morgado MG: Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naive Brazilian blood donors. Transfusion 47, 97-102 (2007). (Pubitemid 46006315)
102. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA: Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J. Acquir. Immune Defic. Syndr. 34, 520-526 (2003). (Pubitemid 37500478)
103. Perez L, Alvarez LP, Carmona R et al.: Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res. Hum. Retroviruses 23, 407-414 (2007). (Pubitemid 46608561)
104. Dilernia DA, Lourtau L, Gomez AM et al.: Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 21, 1355-1360 (2007). ■ Well-designed study based on the WHO criteria for determining TDR in a selected population.
105. Petroni A, Deluchi G, Pryluka D et al.: Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J. Acquir. Immune Defic. Syndr. 42, 506-510 (2006). (Pubitemid 44050902)
106. Barreto CC, Nishyia A, Araujo LV, Ferreira JE, Busch MP, Sabino EC: Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J. Acquir. Immune Defic. Syndr. 41, 338-341 (2006).
107. Paraschiv S, Otelea D, Dinu M, Maxim D, Tinischi M: Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int. J. Infect. Dis. 11, 123-128 (2007). (Pubitemid 46299168)
108. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM: Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J. Antimicrob. Chemother. 59, 517-524 (2007). (Pubitemid 47073459)
109. Jorgensen LB, Christensen MB, Gerstoft J et al.: Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand. J. Infect. Dis. 35, 800-807 (2003). (Pubitemid 38028914)
110. Kousiappa I, van de Vijver DA, Demetriades I, Kostrikis LG: Genetic analysis of HIV type 1 strains from newly infected untreated patients in cyprus: high genetic diversity and low prevalence of drug resistance. AIDS Res. Hum. Retroviruses 25, 23-35 (2009).
111. Vercauteren J, Derdelinckx I, Sasse A et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res. Hum. Retroviruses 24, 355-362 (2008).
112. Abreu CM, Brindeiro PA, Martins AN et al.: Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch. Virol. 153, 2013-2017 (2008).
113. Adje-Toure C, Bile CE, Borget MY et al.: Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02-AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 34, 111-113 (2003). (Pubitemid 37100120)
114. Agwale SM, Zeh C, Paxinos E et al.: Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res. Hum. Retroviruses 22, 22-26 (2006). (Pubitemid 43201513)
115. Bellocchi MC, Forbici F, Palombi L et al.: Subtype ana lysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J. Med. Virol. 76, 452-458 (2005). (Pubitemid 40943252)
116. Bessong PO, Mphahlele J, Choge IA et al.: Resistance mutational ana lysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res. Hum. Retroviruses 22, 1306-1312 (2006). (Pubitemid 46095250)
117. Deho L, Walwema R, Cappelletti A et al.: Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. AIDS Res. Hum. Retroviruses 24, 323-325 (2008). (Pubitemid 351282114)
118. Fleury H, Recordon-Pinson P, Caumont A et al.: HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res. Hum. Retroviruses 19, 41-47 (2003).
119. Fonjungo PN, Mpoudi EN, Torimiro JN et al.: Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features. J. Clin. Microbiol. 40, 837-845 (2002).
120. Gatanaga H, Ibe S, Matsuda M et al.: Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res. 75, 75-82 (2007). (Pubitemid 46610525)
121. Giuliani M, Montieri S, Palamara G et al.: Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. AIDS Res. Hum. Retroviruses 25, 157-164 (2009).
122. Handema R, Terunuma H, Kasolo F et al.: Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res. Hum. Retroviruses 19, 151-160 (2003). (Pubitemid 36308053)
123. Jacobs GB, Laten A, van Rensburg EJ et al.: Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res. Hum. Retroviruses 24, 1009-1012 (2008).
124. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiura W: Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res. Hum. Retroviruses 23, 564-568 (2007).
125. Kinomoto M, Appiah-Opong R, Brandful JA et al.: HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin. Infect. Dis. 41, 243-251 (2005). (Pubitemid 40962507)
126. Konings FA, Zhong P, Agwara M et al.: Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res. Hum. Retroviruses 20, 105-109 (2004). (Pubitemid 38147182)
127. Pandrea I, Robertson DL, Onanga R et al.: Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. AIDS Res. Hum. Retroviruses 18, 1103-1116 (2002). (Pubitemid 35191771)
128. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W et al.: Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int. J. Antimicrob. Agents 31, 277-281 (2008).
129. Toni T, Masquelier B, Bonard D et al.: Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS 16, 488-491 (2002).
130. Bocket L, Yazdanpanah Y, Ajana F et al.: Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. J. Antimicrob. Chemother. 53, 89-94 (2004). (Pubitemid 38072188)
131. Frater AJ, Beardall A, Ariyoshi K et al.: Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1- infected African patients. AIDS 15, 1493-1502 (2001). (Pubitemid 32744596)
132. Laurent C, Kouanfack C, Koulla-Shiro S et al.: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364, 29-34 (2004). (Pubitemid 38968622)
133. Tanuri A, Vicente AC, Otsuki K et al.: Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrob. Agents Chemother. 43, 253-258 (1999). (Pubitemid 29079154)
134. Weidle PJ, Kityo CM, Mugyenyi P et al.: Resistance to antiretroviral therapy among patients in Uganda. J. Acquir. Immune Defic. Syndr. 26, 495-500 (2001). (Pubitemid 32489031)
135. Apetrei C, Descamps D, Collin G et al.: Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J. Virol. 72, 3534-3538 (1998). (Pubitemid 28188648)
136. van de Vijver DA, Wensing AM, Angarano G et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41, 352-360 (2006).
137. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. 7, 1016-1020 (2001).
138. Blower SM, Aschenbach AN, Kahn JO: Predicting the transmission of drug-resistant HIV: comparing theory with data. Lancet Infect. Dis. 3, 10-11 (2003).
139. Vardavas R, Blower S: The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?" PLoS ONE 2, e152 (2007).
140. Blower S, Bodine E, Kahn J, McFarland W: The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19, 1-14 (2005). (Pubitemid 40111013)
141. Brenner BG, Roger M, Moisi DD et al.: Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 22, 2509-2515 (2008).
142. Carrion G, Eyzaguirre L, Montano SM et al.: Documentation of subtype C HIV Type 1 strains in Argentina, Paraguay, and Uruguay. AIDS Res. Hum. Retroviruses 20, 1022-1025 (2004). (Pubitemid 39369710)
143. Delgado E, Leon-Ponte M, Villahermosa ML et al.: Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res. Hum. Retroviruses 17, 753-758 (2001). (Pubitemid 32692413)
144. Ibe S, Hattori J, Fujisaki S et al.: Trend of drug-resistant HIV type 1 emergence among therapy-naive patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006. AIDS Res. Hum. Retroviruses 24, 7-14 (2008).
145. Kim CO, Chin BS, Han SH et al.: Low prevalence of drug-resistant HIV-1 in patients newly diagnosed with early stage of HIV infection in Korea. Tohoku J. Exp. Med. 216, 259-265 (2008).
146. Kojima Y, Kawahata T, Mori H, Oishi I, Otake T: Recent diversity of human immunodeficiency virus type 1 in individuals who visited sexually transmitted infection-related clinics in Osaka, Japan. J. Infect. Chemother. 14, 51-55 (2008). (Pubitemid 351311443)
147. Lloyd B, O'Connell RJ, Michael NL et al.: Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res. Hum. Retroviruses 24, 529-535 (2008). (Pubitemid 351571035)
148. Tossonian HK, Raffa JD, Grebely J et al.: Primary drug resistance in antiretroviralnaive injection drug users. Int. J. Infect. Dis. (2008).
149. Valle-Bahena OM, Ramos-Jimenez J, Ortiz-Lopez R et al.: Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients. Arch. Med. Res. 37, 1022-1027 (2006). (Pubitemid 44540239)
150. Yilmaz G, Midilli K, Turkoglu S et al.: Genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in Istanbul, Turkey. Int. J. Infect. Dis. 10, 286-290 (2006).
151. Vergne L, Peeters M, Mpoudi-Ngole E et al.: Genetic diversity of protease and reverse transcriptase sequences in nonsubtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J. Clin. Microbiol. 38, 3919-3925 (2000).
152. Vergne L, Stuyver L, van Houtte M, Butel C, Delaporte E, Peeters M: Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J. Clin. Virol. 36, 43-49 (2006). (Pubitemid 44382730)
153. Bussmann H, Novitsky V, Wester W et al.: HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir. Chem. Chemother. 16, 103-115 (2005). (Pubitemid 41529730)
154. Nadembega WM, Giannella S, Simpore J et al.: Characterization of drug-resistance mutations in HIV-1 isolates from non- HAART and HAART treated patients in Burkina Faso. J. Med. Virol. 78, 1385-1391 (2006). (Pubitemid 44533865)
155. Tebit DM, Ganame J, Sathiandee K, Nagabila Y, Coulibaly B, Krausslich HG: Diversity of HIV in rural Burkina Faso. J. Acquir. Immune Defic. Syndr. 43, 144-152 (2006). (Pubitemid 44454807)
156. Vergne L, Diagbouga S, Kouanfack C et al.: HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir. Ther. 11, 575-579 (2006). (Pubitemid 44277422)
157. Vidal N, Niyongabo T, Nduwimana J et al.: HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res. Hum. Retroviruses 23, 175-180 (2007). (Pubitemid 46214187)
158. Koizumi Y, Ndembi N, Miyashita M et al.: Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J. Acquir. Immune Defic. Syndr. 43, 15-22 (2006). (Pubitemid 44306482)
159. McNulty A, Jennings C, Bennett D et al.: Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J. Clin. Microbiol. 45, 517-521 (2007). (Pubitemid 46272071)
160. Ndembi N, Abraha A, Pilch H et al.: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J. Clin. Microbiol. 46, 177-184 (2008).
161. Ndongmo CB, Pieniazek D, Holberg-Petersen M et al.: HIV genetic diversity in Cameroon: possible public health importance. AIDS Res. Hum. Retroviruses 22, 812-816 (2006). (Pubitemid 44735010)
162. Tebit DM, Zekeng L, Kaptue L, Salminen M, Krausslich HG, Herchenroder O: Genotypic and phenotypic ana lysis of HIV type 1 primary isolates from western Cameroon. AIDS Res. Hum. Retroviruses 18, 39-48 (2002). (Pubitemid 34133027)
163. Vessiere A, Nerrienet E, Kfutwah A et al.: HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaounde, Cameroon. J. Acquir. Immune Defic. Syndr. 42, 256-258 (2006). (Pubitemid 43884723)
164. Marechal V, Jauvin V, Selekon B et al.: Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. AIDS Res. Hum. Retroviruses 22, 1036-1044 (2006). (Pubitemid 46100690)
165. Punzi G, Saracino A, Brindicci G et al.: HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. J. Med. Virol. 77, 457-459 (2005). (Pubitemid 41609582)
166. Toni TD, Recordon-Pinson P, Minga A et al.: Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study. AIDS Res. Hum. Retroviruses 19, 713-717 (2003). (Pubitemid 37047097)
167. Vidal N, Mulanga C, Bazepeo SE et al.: HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res. Hum. Retroviruses 22, 202-206 (2006). (Pubitemid 43277157)
168. Loemba H, Brenner B, Parniak MA et al.: Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. 56, 129-142 (2002). (Pubitemid 35279662)
169. Caron M, Makuwa M, Souquiere S, Descamps D, Brun-Vezinet F, Kazanji M: Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa. AIDS Res. Hum. Retroviruses 24, 1225-1228 (2008).
170. Vergne L, Malonga-Mouellet G, Mistoul I et al.: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr. 29, 165-168 (2002). (Pubitemid 34164888)
171. Sagoe KW, Dwidar M, Lartey M et al.: Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J. Clin. Virol. 40, 163-167 (2007). (Pubitemid 47419434)
172. Dowling WE, Kim B, Mason CJ et al.: Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS 16, 1809-1820 (2002).
173. Yang C, Li M, Shi YP et al.: Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya. AIDS Res. Hum. Retroviruses 20, 565-574 (2004). (Pubitemid 38720971)
174. Razafindratsimandresy R, Rajaonatahina D, Soares JL, Rousset D, Reynes JM: High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar. AIDS Res. Hum. Retroviruses 22, 595-597 (2006).
175. Petch LA, Hoffman IF, Jere CS et al.: Genotypic ana lysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res. Hum. Retroviruses 21, 799-805 (2005).
176. Derache A, Maiga AI, Traore O et al.: Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J. Antimicrob. Chemother. 62, 456-463 (2008).
177. Derache A, Traore O, Koita V et al.: Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir. Ther. 12, 123-129 (2007). (Pubitemid 46340435)
178. Lahuerta M, Aparicio E, Bardaji A et al.: Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique. AIDS Res. Hum. Retroviruses 24, 327-335 (2008). (Pubitemid 351282098)
179. Ojesina AI, Sankale JL, Odaibo G et al.: Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res. Hum. Retroviruses 22, 770-779 (2006).
180. Servais J, Lambert C, Karita E et al.: HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res. Hum. Retroviruses 20, 279-283 (2004). (Pubitemid 38429400)
181. Vergne L, Kane CT, Laurent C et al.: Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 17(Suppl. 3), S31-SS8 (2003).
182. Razafindratsimandresy R, Hollanda J, Soares JL, Rousset D, Chetty AP, Reynes JM: HIV type 1 diversity in the Seychelles. AIDS Res. Hum. Retroviruses 23, 761-763 (2007). (Pubitemid 47047913)
183. Maphalala G, Okello V, Mndzebele S et al.: Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir. Ther. 13(Suppl. 2), 95-100 (2008).
184. Arroyo MA, Hoelscher M, Sateren W et al.: HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS 19, 1517-1524 (2005). (Pubitemid 41400698)
185. Arroyo MA, Hoelscher M, Sanders-Buell E et al.: HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res. Hum. Retroviruses 20, 895-901 (2004). (Pubitemid 39121210)
186. Nyombi BM, Kristiansen KI, Bjune G, Muller F, Holm-Hansen C: Diversity of human immunodeficiency virus type 1 subtypes in Kagera and Kilimanjaro regions, Tanzania. AIDS Res. Hum. Retroviruses 24, 761-769 (2008). (Pubitemid 351871675)
187. Somi GR, Kibuka T, Diallo K et al.: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir. Ther. 13(Suppl. 2), 77-82 (2008).
188. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, Eshleman SH: Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res. Hum. Retroviruses 16, 807-813 (2000). (Pubitemid 30327297)
189. Church JD, Hudelson SE, Guay LA et al.: HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res. Hum. Retroviruses 23, 764-768 (2007).
190. Gale CV, Yirrell DL, Campbell E, van der Paal L, Grosskurth H, Kaleebu P: Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda. AIDS Res. Hum. Retroviruses 22, 985-992 (2006). (Pubitemid 46100683)
191. Ndembi N, Lyagoba F, Nanteza B et al.: Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res. Hum. Retroviruses 24, 889-895 (2008). (Pubitemid 351871676)
192. Shafer RW, Chuang TK, Hsu P, White CB, Katzenstein DA: Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res. Hum. Retroviruses 15, 65-69 (1999). (Pubitemid 29038326)
193. Saad MD, Aliev Q, Botros BA et al.: Genetic forms of HIV Type 1 in the former Soviet Union dominate the epidemic in Azerbaijan. AIDS Res. Hum. Retroviruses 22, 796-800 (2006). (Pubitemid 44735007)
194. Hai-Long H, Jian Z, Ping-Ping Y et al.: Genetic characterization of CRF01-AE full-length human immunodeficiency virus type 1 sequences from Fujian, China. AIDS Res. Hum. Retroviruses 23, 569-574 (2007).
195. Laeyendecker O, Zhang GW, Quinn TC et al.: Molecular epidemiology of HIV-1 subtypes in southern China. J. Acquir. Immune Defic. Syndr. 38, 356-362 (2005). (Pubitemid 40333504)
196. Liu J, Yue J, Wu S, Yan Y: Polymorphisms and drug resistance ana lysis of HIV-1 CRF01-AE strains circulating in Fujian Province, China. Arch. Virol. 152, 1799 - 1805 (2007).
197. Grossman Z, Lorber M, Maayan S et al.: Drug-resistant HIV infection among drug-naive patients in Israel. Clin. Infect. Dis. 40, 294-302 (2005). (Pubitemid 40110677)
198. Eyzaguirre LM, Erasilova IB, Nadai Y et al.: Genetic characterization of HIV-1 strains circulating in Kazakhstan. J. Acquir. Immune Defic. Syndr. 46, 19-23 (2007). (Pubitemid 47507430)
199. Tee KK, Pon CK, Kamarulzaman A, Ng KP: Emergence of HIV-1 CRF01-AE/B unique recombinant forms in Kuala Lumpur, Malaysia. AIDS 19, 119-126 (2005). (Pubitemid 40409530)
200. Roudinskii NI, Sukhanova AL, Kazennov EV et al.: Diversity of human immunodeficiency virus type 1 subtype A and CRF03-AB protease in eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations. J. Virol. 78, 11276-11287 (2004).
201. Saad MD, Shcherbinskaya AM, Nadai Y et al.: Molecular epidemiology of HIV type 1 in Ukraine: birthplace of an epidemic. AIDS Res. Hum. Retroviruses 22, 709-714 (2006). (Pubitemid 44734996)
202. Carr JK, Nadai Y, Eyzaguirre L et al.: Outbreak of a West African recombinant of HIV-1 in Tashkent, Uzbekistan. J. Acquir. Immune Defic. Syndr. 39, 570-575 (2005). (Pubitemid 41098472)
203. Caumont A, Lan NT, Uyen NT et al.: Sequence ana lysis of env C2/V3, gag p17/p24, and pol protease regions of 25 HIV type 1 isolates from Ho Chi Minh City, Vietnam. AIDS Res. Hum. Retroviruses 17, 1285-1291 (2001). (Pubitemid 32911633)
204. Lan NT, Recordon-Pinson P, Hung PV et al.: HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01-AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res. Hum. Retroviruses 19, 925-928 (2003).
205. Saad MD, Al-Jaufy A, Grahan RR et al.: HIV type 1 strains common in Europe, Africa, and Asia cocirculate in Yemen. AIDS Res. Hum. Retroviruses 21, 644-648 (2005). (Pubitemid 41113652)
206. Ciccozzi M, Gori C, Boros S et al.: Molecular diversity of HIV in Albania. J. Infect. Dis. 192, 475-479 (2005). (Pubitemid 41023126)
207. Paraskevis D, Magiorkinis E, Katsoulidou A et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res. 112, 115-122 (2005). (Pubitemid 40966783)
208. Palma AC, Araujo F, Duque V, Borges F, Paixao MT, Camacho R: Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect. Genet. Evol. 7, 391-398 (2007). (Pubitemid 46667770)
209. Parreira R, Santos M, Piedade J, Esteves A: Natural polymorphism of HIV-1 subtype G protease and cleavage sites. AIDS 18, 1345-1346 (2004). (Pubitemid 38822717)
210. Babic DZ, Zelnikar M, Seme K et al.: Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res. 118, 156-163 (2006).
211. Holguin A, Alvarez A, Soriano V: High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 16, 1163-1170 (2002). (Pubitemid 34533855)
212. Perez-Alvarez L, Carmona R, Munoz M et al.: High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir. Ther. 8, 355-360 (2003). (Pubitemid 37101640)
213. Maljkovic I, Wilbe K, Solver E, Alaeus A, Leitner T: Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01-AE. AIDS Res. Hum. Retroviruses 19, 989-997 (2003).
214. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 31, 215-220 (2004). (Pubitemid 39311801)
215. Tovanabutra S, Brodine SK, Mascola JR et al.: Characterization of complete HIV type 1 genomes from non-B subtype infections in U.S. military personnel. AIDS Res. Hum. Retroviruses 21, 424-429 (2005). (Pubitemid 40800461)
216. HIV Sequence Database. Breakpoints of circulating recombinant forms. www.hiv.lanl.gov/content/sequence/HIV/ CRFs/breakpoints.html (Accessed 1 April 2009).
217. French National Agency for AIDS Research, v17. www.hivfrenchresistance. org (Accessed 1 April 2009).
218. Stanford Database. http://hivdb.stanford.edu (Accessed 1 April 2009).
219. Rega Institute mutation list v8.0.1. www.rega.kuleuven.be/cev/ (Accessed 1 April 2009).